Psychiatrists for Depression in Washington, DC

March 18

by MNTC Team

Depression remains one of the most common and disabling mental health conditions, affecting millions of adults nationwide. For individuals experiencing severe or treatment-resistant depression, accessing specialized psychiatric care can make a profound difference in recovery and quality of life. McLean Hospital, a leading psychiatric institution affiliated with Harvard Medical School, offers adults in the Washington, DC area a pathway to advanced care, combining expert clinicians with innovative neurotherapeutic treatments.

Meet Dr. Stephen J. Seiner: Psychiatric Neurotherapeutics Leader

Dr. Stephen J. Seiner serves as the Director of the Psychiatric Neurotherapeutics Program at McLean Hospital. He also oversees the hospital’s Electroconvulsive Therapy (ECT) Service as Medical Director. His clinical expertise spans neurotherapeutics and geriatric psychiatry, emphasizing evidence-based interventions for individuals with complex depressive disorders. Under Dr. Seiner’s leadership, McLean has developed a comprehensive program that integrates traditional therapies, such as medication management and psychotherapy, with advanced brain-based interventions, including ECT, transcranial magnetic stimulation (TMS), and ketamine therapy.

Patients in the Washington, DC area benefit from Dr. Seiner’s direction through referral networks and consultations. While McLean is located in Massachusetts, its reputation for specialized care ensures that patients and local providers can access advanced neurotherapeutic interventions that are often unavailable elsewhere. Dr. Seiner’s leadership ensures that all treatments adhere to rigorous clinical standards while prioritizing patient safety and individualized care plans.

McLean Offers Advanced Treatment for Depression

McLean Hospital approaches depression treatment with a comprehensive, multi-modal strategy. Standard antidepressants remain an essential component, but many adults with severe or treatment-resistant depression require additional, targeted interventions. McLean’s programs combine medication management with behavioral therapies, including cognitive-behavioral therapy and interpersonal psychotherapy, alongside neurotherapeutic approaches.

The hospital’s residential and outpatient programs provide continuous monitoring and support, ensuring patients remain engaged in care at every stage of recovery. Individuals receive thorough assessments upon entry, allowing clinicians to develop treatment plans that match the severity and characteristics of their depression. By combining multiple interventions under one program, McLean enhances the likelihood of meaningful symptom improvement and sustained recovery. For Washington, DC patients, this approach allows access to treatments that may not be widely available locally, particularly advanced neurotherapies like TMS, ECT, and ketamine therapy.

The Ketamine Service at McLean

One of the most innovative aspects of McLean’s neurotherapeutic program is its Ketamine Service. The hospital offers both intravenous ketamine and FDA-approved intranasal esketamine (Spravato®) for adults with treatment-resistant depression. Ketamine therapy provides rapid relief for many patients who have not responded to conventional antidepressants, often demonstrating measurable symptom reduction after just a few sessions.

The treatment process begins with a thorough evaluation, including medical and psychiatric screening, to ensure patient safety and appropriateness for therapy. Intravenous ketamine infusions typically last around forty minutes, followed by ninety minutes of monitored observation. Intranasal administration, on the other hand, involves approximately 120 minutes of monitoring to track both therapeutic effects and potential side effects. All sessions are conducted in a clinical setting by trained staff, providing structured support and immediate intervention if necessary.

Research at McLean supports the efficacy of ketamine therapy. A study conducted at the hospital involving over 150 adult patients with treatment-resistant depression found that intravenous ketamine produced nearly a 49% reduction in depressive symptoms by the end of the induction phase. Intranasal esketamine demonstrated a decrease of approximately 39% in symptoms. These outcomes highlight ketamine’s potential as a transformative intervention for patients who have not responded to traditional treatments. The program integrates ketamine therapy into a broader neurotherapeutic framework, allowing clinicians to combine it with behavioral therapies, medication adjustments, and other brain-based interventions.

Treatment-Resistant Depression Solutions

Treatment-resistant depression represents a significant challenge in psychiatric care. Many patients fail to achieve relief after multiple antidepressant trials, leaving them with few options and increasing the risk of prolonged disability. McLean addresses this gap through its Psychiatric Neurotherapeutics Program, which provides a spectrum of interventions tailored to complex or refractory cases.

Under Dr. Seiner’s oversight, the program offers TMS, ECT, and ketamine therapy as part of an integrated approach. TMS uses non-invasive magnetic pulses to stimulate brain regions associated with mood regulation, while ECT delivers controlled electrical stimulation to produce therapeutic effects in severe depression. Ketamine therapy, whether intravenous or intranasal, offers rapid symptom relief for some patients. Combined with behavioral therapies and individualized medication management, these interventions create a comprehensive care plan designed to maximize outcomes.

For psychiatrists and patients in Washington, DC, McLean’s program offers an opportunity to access specialized treatments within a structured, research-backed environment. Referrals and collaborative care ensure that patients receive coordinated management while maintaining continuity with their local providers. This model enhances access to high-complexity psychiatric care while supporting long-term recovery.

How to Access Care in the Washington, DC Area

Although McLean Hospital is located in Massachusetts, patients and clinicians in the Washington, DC area can access its advanced neurotherapeutic services through referrals, teleconsultation, and coordinated care agreements. Local psychiatrists can refer patients to the Psychiatric Neurotherapeutics Program, initiating a structured evaluation process that determines eligibility for interventions such as ketamine therapy, TMS, or ECT.

Once a patient is accepted into the program, clinicians develop individualized treatment plans that integrate the patient’s local care team to ensure continuity of care. Teleconsultations allow patients to receive assessments, updates, and guidance remotely, reducing the need for repeated travel while maintaining high-quality care. Care coordination ensures that interventions at McLean complement, rather than replace, ongoing local treatment, creating a collaborative network that supports the patient throughout their recovery journey.

This model allows patients in Washington, DC, to benefit from McLean’s cutting-edge treatments without disrupting their existing healthcare arrangements. It also provides local psychiatrists with access to advanced clinical expertise, research-backed protocols, and innovative neurotherapeutic approaches, thereby enhancing the options available to their patients.

Research and Evidence Supporting Ketamine Therapy

McLean Hospital emphasizes evidence-based care, ensuring that interventions are supported by clinical research. The Ketamine Service, in particular, has been studied extensively within the hospital’s clinical programs. Findings indicate that both intravenous and intranasal ketamine can produce meaningful reductions in depressive symptoms for patients with treatment-resistant depression.

The hospital’s research emphasizes not only symptom reduction but also the importance of integrating ketamine therapy into a comprehensive care plan. Patients often continue to receive behavioral therapy, medication management, and other neurotherapeutic interventions alongside ketamine, reinforcing improvements and supporting longer-term recovery. These research findings provide clinicians and patients in Washington, DC, with confidence in the safety, efficacy, and structured delivery of ketamine therapy within McLean’s program.

Commitment to Patient-Centered Care at McLean

Dr. Seiner and the McLean team prioritize individualized care for each patient. Treatment plans are tailored to the patient’s clinical profile, history, and preferences. The program emphasizes patient safety, thorough monitoring, and collaborative decision-making. Clinicians work closely with patients to identify goals, track progress, and adjust the treatment plan as needed, ensuring that care remains responsive to evolving needs.

For Washington, DC patients, this approach provides both access to specialized treatments and the reassurance of comprehensive oversight. By combining advanced neurotherapeutics with behavioral and pharmacologic interventions, McLean creates a holistic framework that addresses the multifaceted nature of depression.

Ketamine Integration and McLean’s Support Groups

After receiving ketamine therapy, many individuals benefit from structured integration and peer‑support frameworks to maximise gains and sustain progress. At McLean Hospital, patients who complete the Ketamine Therapy program can participate in a variety of support groups designed for ongoing recovery.

These groups include patient-led self-help meetings, family educational forums, and online peer community sessions. They operate both onsite and virtually, enabling flexibility for participants. By participating in these groups, individuals reinforce the therapeutic impact of ketamine, connect with others facing similar challenges, and access life‑skills resources such as job‑coaching or wellness training. These supports ensure that ketamine therapy is not a standalone intervention but an integrated part of a broader recovery journey.

Key Takeaways

Dr. Stephen J. Seiner leads McLean’s Psychiatric Neurotherapeutics Program, providing advanced care for depression.
McLean combines TMS, ECT, and ketamine therapy with behavioral and medication management.
Ketamine therapy demonstrates significant symptom reduction in treatment-resistant depression.
Patients in Washington, DC, can access McLean’s services through referral, consultation, and telehealth coordination.
McLean enhances local psychiatric care with specialized neurotherapeutic options and research-backed protocols.

FAQs

Who qualifies for ketamine therapy at McLean?
Adults affected by major depressive disorder who have not found improvements with multiple antidepressant trials and who are medically cleared may qualify. Screening and monitored sessions are required.
How can Washington, DC psychiatrists refer patients to McLean?
Referrals begin with a consultation with McLean’s Neurotherapeutics Program, including assessment, eligibility determination, and coordination with local providers.
What distinguishes McLean’s ketamine service?
McLean operates within a major academic-affiliated hospital, guided by a specialized team of experts in neurotherapeutics. Research supports its efficacy, and the program integrates ketamine therapy with TMS, ECT, behavioral therapy, and medication management.